Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogenerics Bill From Reps. Eshoo And Barton “Expects” Limits On Substitution

Executive Summary

Interchangeability standards that come close to those sought by the Bush administration are contained in follow-on biologics legislation that is expected to be introduced shortly by Rep. Anna Eshoo, D-Calif
Advertisement

Related Content

Romney Advisor Leavitt Champions Part D As Model For Medicare Reform
Biosimilar Competition Debate: Must Products Be Interchangable To Generate Savings?
Biosimilars Should Face Patent Challenges Only After Approval, Novartis Says
Most Biosimilars Would Need Clinical Trials, ASCO Tells House Panel
Biosimilars Bill From Reps. Eshoo, Barton Gathers Steam In House Cmte.
ESA Market Highlights Need For Follow-On Biologic Pathway – MedPAC
Editor’s Perspective: Is The Ketek Scandal Good For Big Pharma? Generic Biologic Bill Could Suffer
Editor’s Perspective: Is The Ketek Scandal Good For Big Pharma? Generic Biologic Bill Could Suffer
Biosimilar “Interchangeability” Standard Is Double-Edged Sword For Generics
Biosimilar “Interchangeability” Standard Is Double-Edged Sword For Generics
Advertisement
UsernamePublicRestriction

Register

PS049328

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel